MFC1040 program : treatment of pulmonary arterial hypertension (PAH)
MFC1040 is an orally-available, small molecule antagonist of MIF (macrophage migration inhibitory factor) being developed by Mifcare for the treatment of pulmonary arterial hypertension (PAH). MFC1040 shows strong protective effect in animal models of pulmonary hypertension. Preclinical studies are beeing conducted to document pharmacokinetics, safety and tolerance profile of MFC1040.
About pulmonary arterial hypertension (PAH)
With an overall prevalence in the order of 15–50 patients per million, Pulmonary arterial hypertension (PAH) is a rare disorder characterized by an abnormal rise in blood pressure in the pulmonary arteries leading to increased right ventricular afterload and ultimately progressing to right-sided heart failure. Although current available drugs for the treatment of PAH have improved symptoms and quality of life of patients compared to recent years, they don't fight pathogenic mechanisms of PAH, as could do MFC1040. In addition, survival rate associated with these current drugs still needs to be increased.
Research and development of effective and safe drugs with new mechanism of action are therefore needed to better fight PAH.